Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

October 24, 2016October 24, 2016

Pfizer to Begin Shipping Inflectra for RA, Other Illnesses to US Wholesalers in November

News

Pfizer recently announced that its Inflectra (infliximab-dyyb) for injection will be shipped to U.S. wholesalers in late November. Inflectra is a biosimilar of Remicade (infliximab), and is the first FDA approved biosimilar monoclonal antibody ... Read more

September 26, 2016September 26, 2016

GSK Submits Rheumatoid Arthritis Treatment Sirukumab for EU Marketing Authorization

News

GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product sirukumab, a subcutaneous formulation for adults with moderate to severe rheumatoid arthritis (RA). The ... Read more

August 31, 2016August 31, 2016

Biologic DMARD Use May Lower Risk of Deadly Sepsis in RA Patients with Infections

News

Biological disease-modifying anti-rheumatic drugs appear to more effectively reduce the risk of sepsis after serious infection in patients with rheumatoid arthritis (RA) than conventional drugs of this nature, researchers reported, based on a study ... Read more

August 26, 2016August 26, 2016

Phase 3 Clinical Tests of Filgotinib in Range of RA Patients Getting Underway

News

Galapagos NV has recently initiated a global Phase 3 clinical program (FINCH) evaluating the safety and efficacy of filgotinib (100 mg and 200 mg once daily) in a range of ... Read more

August 5, 2016August 5, 2016

Generic Biologic Drugs Appear Comparable to Brand-name Counterparts, According to Review

News

A new Johns Hopkins Bloomberg School of Public Health systematic review indicates that generic forms of a biologic drug for the treatment of rheumatoid arthritis and other autoimmune diseases seem ... Read more

August 3, 2016August 3, 2016

Novel Rheumatoid Arthritis Treatment Developed by BIOCAD

News

BIOCAD has advanced a novel medicine for autoimmune diseases that include rheumatoid arthritis (RA), and psoriatic arthritis (PsA). The company’s new drug candidate BCD-121 is forecast to increase the efficacy of RA treatment up to 20% compared with ... Read more

August 1, 2016August 1, 2016

Navidea’s Phase 1 Trial of Lymphoseek for Rheumatoid Arthritis Gets IRB Approval

News

The University of California, San Francisco School of Medicine has granted Institutional Review Board (IRB) approval to Navidea Biopharmaceuticals to conduct a Phase 1 clinical trial evaluating Lymphoseek (technetium Tc 99m tilmanocept) injection to ... Read more

July 25, 2016July 25, 2016

FDA-approved Orencia ClickJect for Rheumatoid Arthritis Launched by BMS

News

Bristol-Myers Squibb has launched its U.S. FDA-approved Orencia ClickJect Autoinjector for adults with moderate to severe rheumatoid arthritis (RA). Orencia (abatacept) is a modified antibody drug that interferes with the immune activity of T-cells and can treat the symptoms of rheumatoid ... Read more

June 27, 2016June 27, 2016

There’s a Cellular Reason Why Rheumatoid Arthritis May Differ by Location, Researchers Say

News

A team of researchers recently discovered that cellular differences in joints are linked to joint-specific differences in rheumatoid arthritis. Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests itself ... Read more

June 24, 2016June 24, 2016

Phase 3 Study Finds Oral Drug Reduces Joint Damage Caused by Rheumatoid Arthritis

News

Once daily treatment of moderate to severe rheumatoid arthritis with the oral drug baricitinib significantly reduced structural damage to patients’ joints, according to a study presented at the recent EULAR Annual Congress in London. Data for ... Read more